Design and deliver compelling marketing, communications, thought leadership, and brand-building strategies for biotech, pharmaceutical, and non-profit organizations seeking to pioneer new markets, accelerate growth, and navigate transformational change.

Start-up, a public benefit corporation, and CDMO leveraging advanced API manufacturing processes to address critical drug shortages.• Advisor to Chief Executive Officer and Chief Business Officer, leading marketing, public relations, and communications for the corporate brand and the Contract Development and Manufacturing Organization (CDMO).• Established high-performing marketing and communications team also responsible for sustainability and impact. • Launched, revitalized, and streamlined corporate narrative and branding to clarify Phlow’s value proposition to secure government investment, successfully close Series A round, resolve public skepticism, and engage national and trade media. • Transformed social, website, and digital strategy to establish stakeholder credibility, generate high-quality commercial leads, and strengthen corporate reputation and leadership profile.• Delivered 12+ executive visibility and thought leadership events, including FT Pharma and Biotech Summit, CQ Roll Call, and Becker’s Hospital Review; Developed talking points, scripts, and presentations for internal and external presenters.• Spearheaded marketing and communications strategy to launch the first-in-kind Children’s Hospital Coalition, securing membership and long-term purchasing commitments from over 30+ leading national hospitals. • Designed and executed CDMO launch plan, including brand identity creative, unique value proposition, messaging, targeting, segmentation, lead generation, industry conferences, speaking engagements, and public relations.• Acted as a strategic thought partner with industry organizations, regional economic development alliances, strategic partners, and advocacy groups to accelerate shared initiatives and leverage opportunities to advance our common objectives.• Developed and activated a crisis management plan for a congressional investigation and negative media publicity.

Global pharmaceutical company pioneering life-transforming treatments for substance use disorder and serious mental illness.• Reporting to CEO and member of Executive Committee. Led the communication strategy and execution for the public listing of Indivior on the London Stock Exchange.• In less than three months before listing, created the new global corporate identity, including name/trademark, creative branding, Indivior narrative, corporate website, and internal and external change management communications.• Built, coached, and developed a 7-member team, 3 matrix colleagues, and 4 agencies responsible for the corporate, product (3+ product launches), R&D (10+ M&A and R&D milestones), and financial communications (6 annual reports, 2 Investor Days), media relations, and Government Affairs. • Structured and guided a 30-member global communications team to ensure adherence to disclosure and governance requirements, unify branding and messaging, align advocacy and global policy initiatives, and navigate media relations. • Pioneered a global, multi-faceted internal communications program (1,000+ employees), including intranet launch, town halls, milestone and financial updates, employee engagement, and disease awareness events led by patient/advocacy ambassadors. • Established and activated a network of 20+ advocacy, professional, and criminal justice organizations, including patients, to champion disease awareness campaigns (USA Today supplement), advance policy initiatives (congressional testimony, The Hill events), advocate for treatment innovation and expanded access (FDA Advisory Panel, ASAM Nurse Practitioner certification). • Developed enterprise-wide issues and crisis management plan; Activated for high-profile events, including product quality and diversion risks, government investigations, and layoffs.

• Pioneered the first-ever, research based, multiple scenario 10-year plan with P&Ls for North America (US and Canada.)• Lead HCP, patient, and payor market research to inform long-term optimization strategy for the North America pipeline portfolio including payor access strategy, pricing, and channel distribution.• Advised and collaborated with Clinical R&D, Medical and Regulatory teams to generate insight-driven target product profiles, differentiated product claims, and robust patient centered outcomes and HEOR studies to maximize launch success.

• Led North America lifecycle and go-to-market plans for $1.5B SUBOXONE® franchise - medical treatments for opioid use disorder, a highly stigmatized and misunderstood chronic disease. • Built and developed an award-winning marketing team (10); Initiated the Marketing Insights and Needs Development Team comprised of 30 field team members to provide real-time feedback. • Visioned and executed SUBOXONE® Film positioning and go-to-market strategy; Led cross-functional team to over-deliver launch KPIs while managing a $30M budget; Market share significantly exceeded plan.• Developed and executed managed care and trade distribution strategy, including pricing, and copay cards for SUBOXONE® franchise; Exceeded SUBOXONE® Film post-launch commercial (85%) and public (90%) formulary availability targets. • Established a speakers’ bureau supported by Medical Affairs and Compliance, including national speaker training for 250+ HCPs, including physicians, pharmacists, and counselors.• Pioneered award-winning, direct-to-patient campaign including websites, CRM, social media, PPC digital ads, search engine marketing, journal placements, TV and radio advertising, and patient and physician testimonials (2.85 ROI and 15+M NR).• Grew SUBOXONE® franchise prescribers by 20%+ YOY; Optimized SEM investment to drive 5M+ unique website visitors yielding 850K+ “find a doctor “searches.• Designed and implemented successful strategic marketing efforts for the Canadian market exceeding objectives by 30%.• Collaborated with Sales Training to set strategy and objectives for training efforts, including national sales meetings, train-the-trainer sessions, and workshops for 200+ sales representatives.• Engaged with KOLs to inform the brand strategy, educational initiatives, promotional programs, and develop diagnostic and treatment algorithms.• Provided strategic insights, market forecast assumptions, and commercial perspectives for Business Development M&A diligence projects (11+).

Direct report to Global President; Led and executed North America lifecycle and go-to-market plans for SUBOXONE® franchise - highly-regulated, schedule III medical treatments for opioid use disorder, a highly stigmatized and misunderstood chronic disease.